Manganese Side Effects

Reported Manganese side effects

Dietary manganese intake at the AI (2-3 mg/day) is well tolerated with no characteristic adverse effects. Supplementation at multivitamin levels (1-2 mg/day) is comparably safe. Above approximately 10-11 mg/day (the UL), cumulative exposure risks increase; above 20 mg/day chronic intake, meaningful toxicity risk emerges. Neurologic — manganism. The primary toxicity concern. Early symptoms: irritability, emotional lability, insomnia, headaches, difficulty concentrating, mild cognitive slowing, sometimes agitation or impulse dyscontrol ("locura manganica" in the classical Chilean literature on manganese miners). Progression: bradykinesia, rigidity, masked facies, postural instability, dystonia, "cock-walk" gait with hyperextension, micrographia, dysarthria, dysphagia — a parkinsonian syndrome with pallidal rather than nigral distribution. Unlike idiopathic PD, tremor is less prominent, levodopa response is poor or absent, and MRI T1-hyperintensity in globus pallidus is characteristic. The syndrome may partially reverse with exposure cessation in early stages but becomes permanent with advanced disease. Associated with welding, mining, smelting, battery manufacturing, MMT gasoline exposure, long-term parenteral nutrition, cholestatic liver disease, and SLC30A10/SLC39A14 Mendelian disorders. Hepatic — manganese accumulation in liver disease. Cholestatic liver disease, biliary obstruction, and cirrhosis of any etiology impair biliary manganese excretion leading to accumulation in liver and brain. The MRI T1-hyperintensity in globus pallidus seen in cirrhotic patients (particularly with portosystemic shunting) is a signature of this. Manganese may contribute to hepatic encephalopathy symptoms. Liver transplantation reverses the imaging findings over weeks to months. Pulmonary — occupational. Inhaled manganese fumes (welding, smelting) can cause manganese pneumonitis at high exposures and chronic bronchitis with long-term lower-level exposure. Manganese pneumonia has been described historically in manganese miners. Pregnancy and developmental. Chronic high manganese exposure in pregnancy is associated with increased miscarriage risk, reduced birth weight, and child neurodevelopmental impact in observational studies (primarily from environmental exposure cohorts). Supplement use within the pregnancy AI (2.0 mg/day) is safe; high-dose supplementation should be avoided. Iron metabolism. High manganese intake competes with iron for DMT1 absorption and can contribute to functional iron deficiency, particularly in vegetarians and in populations with marginal iron status. Iron deficiency reciprocally increases manganese absorption, creating a potentially vicious cycle. Gastrointestinal. Supplements at doses of 5-20 mg/day may cause mild dyspepsia, nausea, or altered bowel habits in some users; effects are usually modest and self-limiting. Acute toxicity. Acute oral manganese toxicity is rare due to poor absorption. Intravenous accidental overdose (e.g., TPN infusion error, industrial exposure) can produce acute hepatotoxicity, metabolic acidosis, and potentially acute manganism. Drug interactions. Manganese absorption is reduced by antacids, PPIs (less well documented than for iron/calcium but expected), bisphosphonates, fluoroquinolones (chelation). Manganese may interact with tetracycline absorption (chelation). Coadministration with calcium, magnesium, or zinc supplements may reduce manganese absorption. Occupational monitoring. Whole blood manganese, serum manganese, urinary manganese, and neurologic/neuropsychologic screening are components of occupational surveillance in welders, miners, and battery workers in regulated jurisdictions. Populations to avoid manganese supplementation. Patients with liver disease (any etiology), cholestasis or biliary obstruction, infants on parenteral nutrition without specific indication, patients with known manganese exposure (occupational, environmental), patients with iron-deficiency anemia (supplement iron first — may reduce manganese accumulation), and patients with known SLC30A10 or SLC39A14 mutations.

When to continue, reduce, or stop Manganese

Manganese contraindications

Absolute contraindications: Chronic liver disease of any etiology with cholestasis or biliary obstruction (impaired excretion). Cirrhosis with portosystemic shunting. Known SLC30A10 or SLC39A14 mutations (Mendelian hypermanganesemia). Diagnosed manganism or occupational manganese overexposure. Long-term parenteral nutrition in presence of cholestasis (use manganese-free TPN). Children with neurologic regression or MRI globus pallidus T1-hyperintensity of unknown cause (pending evaluation). Relative contraindications / use only with medical supervision: Iron-deficiency anemia (treat iron deficiency first; iron deficiency increases manganese uptake). Pregnancy with environmental manganese exposure. Occupational welding, mining, smelting, battery manufacturing (rely on diet, avoid supplements). Long-term proton pump inhibitor use (increased bioavailability). Chronic kidney disease (manganese handling is not primarily renal, but abnormal mineral balance may coexist). Parkinsonian syndromes of unclear etiology (manganism in differential). Populations requiring dose adjustment: Elderly with mild hepatic dysfunction: use conservative dosing (multivitamin only, no standalone manganese). Pediatric: do not exceed age-appropriate AI. TPN patients: work with nutrition support team to optimize manganese content. Clinical warning signs — stop manganese supplementation and seek evaluation: New-onset parkinsonism or dystonia. Irritability, emotional lability, or cognitive change in context of known exposure. Abnormal liver function tests. MRI evidence of globus pallidus abnormality. Elevated whole-blood manganese on any routine laboratory assessment. Drug interaction caveats: Tetracyclines, fluoroquinolones: chelation reduces antibiotic absorption (separate by 2-4 hours). Bisphosphonates: similar chelation concern (separate by 2 hours). Levodopa: pharmacodynamic overlap in basal ganglia; consult neurology before any manganese supplementation in PD patients (generally contraindicated). Lactation: AI is higher during lactation (2.6 mg/day) because of milk losses; normal diet typically covers this. Avoid high-dose supplements. Regulatory status: Manganese supplements are regulated as dietary supplements in the US (FDA 1994 DSHEA). No FDA approval for treatment of any disease at consumer doses. Pharmaceutical formulations (e.g., IV manganese for TPN) are regulated as drugs.

Why vendor quality drives Manganese side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Manganese side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .